Drug Trial Radar · NCT06885996
Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Aug 1, 2028
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- University of CalgaryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Vancouver Island University; University of British Columbia
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized controlled trial is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress disorder (PTSD) symptom burden in adult (aged 18-65) survivors of intimate partner violence (IPV). This trail will test the following 2 aims: AIM 1 : To compare the efficacy of a therapeutic psilocybin dose at improving outcomes on the PCL-5 and CAPS-5 as compared to an active control psilocybin dose in IPV survivors with chronic PTSD. AIM 2: To evaluate the efficacy of psilocybin on quality of life, cognitive function, motor ability, depression, anxiety, and cognitive flexibility. Participants will be asked to: * Complete a 2 part screening process * Attend a baseline assessment * Complete a psychoeducation preparation session(s) * Attend psilocybin administration session (receive high dose \[25mg\] or low dose psilocybin \[1mg\]) * Complete 5-6 weekly sessions of ACT * Repeat outcome measures at 1-week, 4 weeks, 3 months (online questionnaires only), and 6 months post-psilocybin administration.
Conditions
- Post Traumatic Stress Disorder PTSD
- Intimate Partner Violence (IPV)
Interventions
PsilocybinDrug
See treatment arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)Time frame: Change from baseline to 1-week, 4 weeks, and 6 months post-dosing
- PTSD Checklist for DSM-5 (PCL-5)Time frame: Change from baseline to 1-week, 4 weeks, and 3 months, and 6 months post-dosing
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada
The University of British Columbia - Okanagan Campus
Kelowna, British Columbia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.